Abstract. Mutations in the mitochondrial 12S ribosomal
Introduction
Deafness is a serious health problem with unknown etiology, and it is estimated that 1 in 1,000 newborns suffer from the condition (1) . It may be associated with numerous risk factors, including the administration of aminoglycoside antibiotics (AmAn) (2) . Genetic alterations in human mitochondrial (mt)DNA are also thought to be associated with deafness (3) . Human mtDNA is a double-stranded, circular molecule, encoding 13 protein subunits, 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs). In particular, the well-known 12S rRNA A1555G mutation has been demonstrated to be an important molecular basis of hearing loss (4, 5) . Furthermore, the A to G transition at position 1555 is located in the region of small ribosomal RNA that is highly conserved in bacteria and mammals (6) . The corresponding region in Escherichia coli forms an essential part of the decoding site of the ribosome (7) and is crucial for subunit association either by RNA-protein or the RNA-RNA interaction (8) . It is interesting to note that among individuals who carry this mutation, the use of AmAn for clinical treatment of fever is likely to result in irreversible hearing impairment (9) . However, individuals who carry the A1555G mutation exhibit a wide range of clinical phenotypes, from profound hearing loss to normal hearing (4) . Thus, if an individual carrying the A1555G mutation cannot use aminoglycosides, screening for the A1555G mutation is crucial for prevention and early diagnosis of maternally inherited deafness. In addition, lymphoblastoid cell lines derived from an Arab-Israeli family demonstrated more severe biochemical defects in those that were symptomatic to those that were not (10) . Therefore, it is hypothesized that other unidentified risk factors, including polymorphisms in mtDNA, nuclear gene mutations, AmAn and epigenetic modification, may contribute to hearing impairment (10) .
To explore the potential association between mtDNA polymorphisms and deafness, a mutational screening was conducted for the presence of A1555G in 300 infants with hearing impairment and 100 healthy controls. Consequently, 5 patients with the mutation were identified. Among these infants carrying the A1555G mutation, only one had a family history of exposure to AmAn. ). Subsequently, the PCR products were purified and sequenced using the ABI PRISM™ 3700 machine (Applied Biosystems; Thermo Fisher Scientific, Inc.) (11) . A total of 24 PCR product sequences were compared with the reverse Cambridge sequence, using DNA Star software version 5.01 (DNASTAR Inc., Madison, WI, USA) to detect variations in mitochondrial genes (GenBank accession no. NC_012920) (12) .
Analysis of mitochondrial A1555G mutation in infants with hearing impairment
Phylogenetic conservation analysis. To discern the potential pathogenic mtDNA mutations, the phylogenetic approach was utilized to assess the conservation index (CI) of each mtDNA mutation. A total of 17 species were used to analysis the CIs. Notably, CI>75% was regarded as exhibiting functional potential (13) .
Detecting GJB2 mutations. In order to identify whether GJB2 mutations were involved in hearing impairment, variants of GJB2 were screened using PCR and direct sequencing. The primers for amplification of the GJB2 coding region were as follows: Forward, 5'-TAT GAC ACT CCC CAG CAC AG-3' and reverse, 5'-GGG CAA TGC TTA AAC TGG C-3' (14) . The PCR reagents (all obtained from Takara Bio, Inc.) were as follows: 200 µM dNTPs, 2 µl 10X PCR buffer (10x0.2 µl Taq DNA polymerase) and 15 mmol/l Mg
2+
. PCR was performed under the following thermocycling conditions: 95˚C for 5 min, 94˚C for 10 sec, 60˚C for 30 sec, 30 cycles at 72˚C for 60 sec, and 72˚C for 10 min for extension Then, the PCR products were sequenced using the ABI PRISM™ 3700 machine (Applied Biosystems; Thermo Fisher Scientific, Inc.) and compared with the wild-type GJB2 sequence using DNA Star software version 5.01 (GenBank accession no. M86849) to detect potential pathogenic mutations.
Screening for the TRMU A10S variant. Nuclear modified gene TRMU was previously identified to be associated with hearing loss (15) . To understand the role of TRMU in hearing impairment, the TRMU A10S variant was screened in the matrilineal relatives using PCR amplification of exon 1 of this gene. The PCR reagents (all obtained from Takara Bio, Inc.,) were as follows: 200 µM dNTPs, 2 µl 10X PCR buffer (10x0.2 µl Taq DNA polymerase) and 15 mmol/l Mg 2+ . The primer sequence for exon 1 was as described previously (15) . PCR was performed under the following thermocycling conditions: 95˚C for 5 min, 94˚C for 10 sec, 58˚C for 30 sec, 30 cycles at 72˚C for 60 sec, and 72˚C for 10 min for extension. Then, the PCR product was sequenced using the ABI PRISM™ 3700 machine (Applied Biosystems; Thermo Fisher Scientific, Inc.) and compared with the wild-type version of TRMU and DNA Star software version 5.01 (GenBank accession no. AF448221) (16) .
Bioinformatics analysis. To investigate whether T15943C mutation altered the structure of tRNA Thr , the RNA Fold web server was employed to analyze the secondary structure of tRNA Thr with and without the T15943C mutation (http://rna.tbi. univie.ac.at/cgi-bin/RNAfold.cgi) (17) . The wild-type version of tRNA Thr gene was: 5'-GTC CTT GTA GTA TAA ACT AAT ACA CCA GTC TTG TAA ACC GGA GAT GAA AAC CTT TTT CCA AGG ACA-3'. The sequence of tRNA Thr gene carrying the T15943C mutation was: 5'-GTC CTT GTA GTA TAA ACT AAT ACA CCA GTC TTG TAA ACC GGA GAT GAA AAC CTT TCT CCA AGG ACA-3'.
Results
Frequency of mitochondrial A1555G mutation in infants with deafness. To detect the allele frequency of the A1555G mutation, 300 infants were enrolled who were confirmed to have non-syndromic hearing loss by a clinical physician in Fujian Provincial Hospital. The restriction enzyme BsmAI was used to screen the mitochondrial A1555G mutation following PCR amplification of the 12S rRNA gene. As indicated in Fig. 1 , following electrophoresis, it was observed that samples carrying the A1555G mutation exhibited only one 797 bp band, while the samples without this mutation resulted in two specific bands: 472 and 325 bp. Consequently, 5 patients with this mutation were identified (5/300; 1.67%). The mutation was not detected in the 100 healthy controls. Further clinical evaluation indicated that 1 patient with the mutation had an obvious family history of using AmAn.
Molecular characterization of the pedigree carrying mitochondrial A1555G mutation. The proband's mother (II-10) was 26 years old and came from the Fuzhou area of Fujian Province, China. She received AmAn (gentamycin, 5 mg/kg/dose) for clinical treatment of a high fever when she was 21 years old. Unfortunately, 2 weeks following the antibiotic treatment, she suffered from bilateral hearing loss and clinical examination indicated that she had severe deafness (75 dB in left ear, 88 dB in right ear; see Table I ). Further physical and audiological examinations were performed for the matrilineal relatives in this family. It was observed that I-2, II-5 and II-8 had a history of exposure to AmAn.
As indicated in Fig. 2 , this pedigree had an obvious maternal transmission pattern. It was noted that the pedigree manifested a high penetrance and expressivity of deafness: The penetrance of deafness was 80 and 40% when patients who were exposed to AmAn were included and excluded, respectively. Furthermore, it was identified that the age at onset of deafness varied from 1 to 55 years (Table I ). Other members of this family did not exhibit any other mitochondrial disorders, including type 2 diabetes, cardiovascular events, vision loss or neurological diseases.
Screening for mutations in mitochondrial genes.
The maternally inherited pattern of this family indicated that mitochondrial dysfunction may be involved in the pathogenesis of hearing loss. In order to investigate this, the variants in mtDNA were screened using PCR and direct sequencing. The results indicated that matrilineal relatives (I-2, II-1, II-5, II-8, II-10, III-9, III-10 and III-12) in this family harbored 22 mtDNA polymorphisms, as well as the well-known A1555G mutation (Table II) . Of these, six variants were identified in the D-loop, three variants in 12S rRNA, one variant in 16S rRNA and one mutation in tRNA Thr . The other sequence alterations were primarily in oxidative phosphorylation-associated genes. Furthermore, there were six missense mutations, including ND2 C5178A (L237M) and A5301G mutations (I278V), ATP6 A8860G mutation (T112A), ND3 A10398G mutation (T114A), and CytB C14766T (T7I) and A15326G (T194A) mutations. In addition, evolutionary conservation analysis was performed for these variants between 17 vertebrates, including the mouse (18) , bovine (19) and Xenopus laevis (20) . However, it was identified that none of these variants were conserved, with the exception of A1555G and T15943C mutations ( Fig. 3 and Table III ). In addition, the A1555G and T15943C mutations were absent in the control subjects. This suggested that the A1555G and T15943C mutations were involved in the pathogenesis of deafness in this family.
Genotyping analysis of GJB2 gene.
To evaluate the contribution of GJB2 gene variants to deafness expression, GJB2 mutations were analyzed in the matrilineal relatives (I-2, II-1, II-5, II-8, II-10, III-9, III-10 and III-12). However, no functional variants were observed in the GJB2 gene.
Mutational analysis of TRMU gene.
A previous study indicated that the TRMU A10S variant may contribute to the clinical expression of hearing loss associated with mitochondrial A1555G mutation (15) . Therefore, the TRMU A10S variant was screened in matrilineal members from the current pedigree (I-2, II-1, II-5, II-8, II-10, III-9, III-10 and III-12). However, the variant was not detected in these subjects.
T15943C mutation affects the secondary structure of tRNA

Thr
. To evaluate the effect of T15943C mutation on tRNA Thr , a bioinformatics tool was used to predict the tRNA Thr secondary structure with and without this mutation (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) (17) . As indicated in Fig. 4 , the T15943C mutation notably altered the tRNA Thr secondary structure, strongly indicating that this mutation was pathogenic.
Discussion
The current study screened the occurrence of mitochondrial A1555G mutation in pediatric subjects with hearing loss. As early as 1993, the A1555G mutation was reported in an Arab-Israeli family with non-syndromic hearing impairment (4). In fact, this mutation occurred in the A-site of 12S rRNA gene, which was strongly conserved between multiple species and was critical for the binding of AmAn (21, 22) . Therefore, patients carrying A1555G mutation were more vulnerable to developing hearing loss when using AmAn.
Using PCR and direct sequencing, 5 infants with hearing loss were identified to be carrying the A1555G mutation in the current study. Its frequency was 1.67% in patients, but the mutation was not detected in the control subjects. The frequency of the A1555G mutation varies worldwide. For patients with hearing loss who used AmAn, the frequency of the A1555G mutation was reported to be 33% in a Japanese population (23), whereas the incidence was reported to be 13, 10.4 and 5% in three Han Chinese populations (24) (25) (26) . These data are important, since children who carry this mutation should not be exposed to AmAn. Thus, screening for the occurrence of the A1555G mutation is advisable, particularly for those who have a family history of using AmAn.
In the current study, 5 infants with hearing loss were identified to be carrying the homoplasmic A1555G mutation. However, only 1 of these patients had an obvious family history of using AmAn. Following comprehensive genetic counseling, it was identified that the family members only exhibited the deafness phenotype, without other common diseases, including type 2 diabetes mellitus, cardiovascular events and neurological disorders. In addition, the pedigree manifested a high expressivity of deafness. PCR-Sanger sequencing was performed to identify the occurrence of the homoplasmic A1555G mutation, together with a further 22 genetic variations belonging to the East Asian haplogroup C (20) . Among these, the T15943C mutation in tRNA Thr was of particular interest. This mutation was identified in this Chinese family with hearing loss (Patients: I-2, II-1, II-5, II-8, II-10, III-9, III-10 and III-12) but absent in 100 healthy subjects. In addition, this mutation occurred at an evolutionary conserved position of tRNA Thr (conventional position 63), which could disrupt 63T-55A base pairing and may result in failures in tRNA metabolism. In fact, RNA Fold results also indicated that this mutation caused a structural change of tRNA Thr . Thus, it was speculated that the T15943C mutation affects tRNA Thr function via the alteration of its secondary structure.
The phenotypic variability of matrilineal relatives within the pedigree suggested that nuclear genes or mtDNA genetic modifiers may serve key functions in deafness expression. For example, the TRMU A10S variant has previously been reported to increase the penetrance and expressivity of deafness-associated mitochondrial A1555G mutation (15) . Mutations in the GJB2 gene have been regarded as important causes for non-syndromic hearing loss (14) . However, an absence of functional sequence variants in TRMU and GJB2 genes in the current study indicated that these genes may not play active roles in deafness expression. Hence, other unidentified nuclear genes may be involved in the clinical manifestation of deafness in this pedigree.
In conclusion, the tRNA Thr T15943C may be a secondary mutation for the phenotypic expression of mitochondrial deafness, and should be regarded as a risk factor for hearing impairment. Furthermore, screening for the presence of mitochondrial A1555G mutation is advisable, particularly for those who have a family history of using AmAn. The primary limitation of this study was the small sample size; further studies including larger cohorts of patients with hearing impairment should be performed in the future. 
